Infirmacea
Infirmacea is a biotechnology company dedicated to developing gene therapies with the mission to extend healthy lifespan and improve quality of life. They aim to revolutionize healthcare through safe and accessible gene treatments, focusing on revitalizing aging, maximizing gene therapy effectiveness with their proprietary gBoost™ technology, and targeting obesity and aging-related diseases. Their vision is to create a future where aging does not compromise health, contributing to a sustainable society.
Industries
Nr. of Employees
small (1-50)
Products
Delivery optimization technology (licensed)
A delivery-enhancing technology that increases gene expression in target cells and is compatible with both viral and non-viral delivery systems; designed to improve safety and cost-effectiveness of gene therapies.
Ex vivo human adipose tissue culture platform
An ex vivo platform using surgically obtained subcutaneous adipose tissue to evaluate therapeutic effects, cell interactions, and human-specific responses for research and preclinical development.
Plasmid-based DNA therapeutic programs (anti-obesity focus)
R&D-stage plasmid DNA therapeutic programs aimed at reducing adipose mass while preserving muscle mass to address obesity and related metabolic disorders.
Delivery optimization technology (licensed)
A delivery-enhancing technology that increases gene expression in target cells and is compatible with both viral and non-viral delivery systems; designed to improve safety and cost-effectiveness of gene therapies.
Ex vivo human adipose tissue culture platform
An ex vivo platform using surgically obtained subcutaneous adipose tissue to evaluate therapeutic effects, cell interactions, and human-specific responses for research and preclinical development.
Plasmid-based DNA therapeutic programs (anti-obesity focus)
R&D-stage plasmid DNA therapeutic programs aimed at reducing adipose mass while preserving muscle mass to address obesity and related metabolic disorders.
Services
Licensing and customization of delivery-optimization technology for external gene- and cell-therapy developers.
Preclinical testing and biological evaluation using an ex vivo human adipose tissue culture system to assess human-specific responses and support therapy optimization.
Licensing and customization of delivery-optimization technology for external gene- and cell-therapy developers.
Preclinical testing and biological evaluation using an ex vivo human adipose tissue culture system to assess human-specific responses and support therapy optimization.
Expertise Areas
- Gene therapy development
- Plasmid DNA therapeutics
- Delivery optimization for gene therapy
- Ex vivo human tissue evaluation
Key Technologies
- Plasmid-based DNA therapeutics
- Viral and non-viral vector delivery optimization
- Transgene expression enhancement
- Ex vivo human adipose tissue culture platform
News & Updates
Selected for hands-on support system for overseas expansion by JETRO.
Participated in JVHS 2024 at Pacifico Yokohama from October 9-11, 2024.
An article was published about the company in Chiba Nippo.
Participated in the regional entrepreneur course by the Ministry of Economy, Trade and Industry.
Awarded at the 38th Business Plan Presentation supporting Chiba's future.
An article introducing Infirmacea in Chiba Nippo.
Selected for hands-on support system for overseas expansion by JETRO.
Participated in JVHS 2024 at Pacifico Yokohama from October 9-11, 2024.
An article was published about the company in Chiba Nippo.
Participated in the regional entrepreneur course by the Ministry of Economy, Trade and Industry.
Awarded at the 38th Business Plan Presentation supporting Chiba's future.
An article introducing Infirmacea in Chiba Nippo.